Guidelines For Clinical Practice
Copyright ©2010 Baishideng.
World J Hepatol. Feb 27, 2010; 2(2): 58-64
Published online Feb 27, 2010. doi: 10.4254/wjh.v2.i2.58
Table 2 Recent phase II studies of chemotherapy for biliary tract carcinoma
AgentsnRR (%)PFS (M)MST (M)AuthorsYear
Gemcitabine
1000mg/m2, 30-min infusion25366.9Gallardo2001
2412.52.57.2Lin2003
4017.52.67.6Okusaka2006
Fluoropyrimidine
Capecitabine26198.1Patt2004
S-119213.78.3Ueno2004
S-14032.53.79.4Furuse2008
Others
Docetaxel24206.08.0Papakostas2001
CPT-113682.76.1Alberts2002
Erlotinib4282.67.5Philip2006
Gemcitabine + fluoropyrimidine
Gem/5FU27333.75.3Knox2004
Gem/5FU/LV30203.74.7Hsu2004
Gem/5FU/LV42124.69.7Alberts2005
Gem/capecitabine45317.014.0Knox2005
Gem/capecitabine45326.014.0Cho2005
Gemcitabine + platinum
Gem/cisplatin30374.14.6Doval2004
Gem/cisplatin40284.78.4Thongprasert2005
Gem/cisplatin29353.011.0Kim2006
Gem/cisplatin27335.610.0Park2006
Gem/oxaliplatin33335.715.4Andre2004
Gem/oxaliplatin/bevacizumab26297.6Clark2007
Fluoropyrimidine + platinum
Capecitabine/oxaliplatin65206.512.8Nehls2006
S-1/cisplatin51304.88.7Kim2007